Skip to main content

UBI company Inficure in new global collaboration agreement with biotech giant CSL

Pressmeddelande   •   Okt 09, 2018 15:28 CEST

Dan Holmberg and Sofia Mayans, founder of Inficure Bio.

Inficure Bio has signed a contract for global collaboration through which CSL will use Inficure’s N-IF test model.

Inficure Bio has developed a new mouse model, the N-IF model. Mice are used as model organisms for studying human biology due to the genetic and physiological conformity between mice and humans. N- IF mice are unique as they spontaneously develop pathological fibrosis, rather than it being induced. This pathological progress is therefore more natural and provides better and faster results.

CSL will collaborate with Inficure in testing their experimental anti-fibrotic reagent in the N-IF mouse.

CSL is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. For over 100 years, CSL has been driven by its promise to save lives using the latest technologies. Today, CSL ‒ including its two businesses, CSL Behring and Seqirus ‒ provides life-saving products to more than 60 countries and employs 22,000 people. The company’s unique combination of commercial strength, R&D focus and operational excellence enables it to identify, develop and deliver innovations so patients can live life to the fullest.

– This collaboration with CSL is tremendously important for us. CSL is the world’s fifth largest biotech company with a long history of successful research and innovation. They have an excellent track record in research commercialisation so this partnership reflects well on the quality and potential of the model we have developed, says Sofia Mayans, CEO Inficure Bio, and continues:

– Prospective partners often ask about who else we are working with. We are very proud to be able to now advise that we are working with one of the world’s leading biotech companies.

Inficure now anticipates that future potential partners will better understand the benefits of the model.

International competition from day 1

Inficure has previously carried out tests for an American company from Boston, now they are collaborating with an Australian company. The link between Umeå and Australia originated with a research group at Umeå University.

For more information, contact:

Sofia Mayans, PhD, CEO, Inficure Bio AB
sofia.mayans@inficurebio.com
+46 (0)70 – 36 64 666
inficurebio.com

Elias Eriksson
PR- and Communication
elias.eriksson@ubi.se
+46760 – 80 79 38
ubi.se

About Inficure

InfiCure Bio is a life science company focused on preclinical development and validation of drugs that target chronic inflammatory and fibrotic conditions.

Based on a panel of in vivo models for these conditions including a proprietary model for chronic inflammation and fibrosis, we offer effect tests of anti-inflammatory and anti-fibrotic drugs.

Founded on extensive experience and expertise in immunology, inflammation and fibrosis research, InfiCure Bio offers proficient and flexible processing of drug validation projects in this area.

Umeå Biotech Incubator (UBI) is one of Sweden’s state-of-the-art business incubators within the life sciences. We help researchers to use their data to the benefit of patients and citizens, improving their health. We support and train entrepreneurs in the fields of pharmaceuticals, diagnostics and medical engineering, and act as a bridge between academia, medicine and the business community.

Kommentarer (0)

Lägg till kommentar

Kommentera

Genom att skicka din kommentar accepterar du att dina personuppgifter behandlas i enlighet med Mynewsdesks Integritetspolicy.